

**From:** Clinician Outreach and Communication Activity (CDC)  
**Sent:** Monday, December 29, 2008 12:54 PM  
**To:** Clinician Outreach and Communication Activity (CDC)  
**Subject:** CDC Updates for Clinicians: Dec 22 - 29, 2009



December 29, 2008

The following updates were made to CDC information and guidance from **Dec - 22 - 29**. If you have any questions on these or other clinical issues, please write to us at [coca@cdc.gov](mailto:coca@cdc.gov).

**Today's topics include:**

[Emerging Infectious Disease \(EID\) Journal](#)  
[Seasonal Influenza](#)  
[Emergency Preparedness](#)  
[Drug Safety](#)  
[Travelers' Health](#)

## Emerging Infectious Disease (EID) Journal

The Emerging Infectious Diseases (EID) journal provides recognition of new and re-emerging infections and understanding of factors involved in disease emergence, prevention, and elimination. It also represents the scientific communications component of CDC's efforts against the threat of emerging infections. See the **January 2009** issue of the EID journal at the following link:

<http://www.cdc.gov/ncidod/EID/index.htm>

## Seasonal Influenza

**Weekly Report: Influenza Summary Update - CDC - Dec. 26**

During week 50 (December 7-13, 2008), a low level of influenza activity was reported in the United States.

<http://www.cdc.gov/flu/weekly/>

**Weekly US Map - Dec. 26**

<http://www.cdc.gov/flu/weekly/usmap.htm>

## Emergency Preparedness

**FDA Approves BioThrax Supplemental Biologics License Application - FDA - Dec.**

The U.S. Food and Drug Administration (FDA) has approved Emergent BioSolutions Inc's supplemental Biologics License Application (BLA) for Anthrax Vaccine Adsorbed (BioThrax), the only FDA-licensed vaccine to prevent disease caused by Bacillus anthracis. The revised package insert to include a change in schedule from 0, 2, 4 weeks and 6, 12 and 18 months to 0, 4 weeks, and 6, 12, and 18 months, and a change in route of administration from subcutaneous to intramuscular.

<http://www.fda.gov/cber/approvtr/biothrax121108L.htm>

## Drug Safety

**ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets Due to Potential for Oversized Tablet - FDA - Dec. 23**

ETHEX Corporation announced today that it has voluntarily recalled to the consumer level, a single production lot of Hydromorphone HCl 2 mg tablets (Lot #90219, Exp: 03/2010; NDC #58177-0620-04), as a precaution, due to the possibility it may contain oversized tablets.

[http://www.fda.gov/oc/po/firmrecalls/ethex12\\_08.html](http://www.fda.gov/oc/po/firmrecalls/ethex12_08.html)

## Travelers' Health

### Rabies in Bali, Indonesia - CDC - Dec. 22

On December 18, 2008, the Indonesian Ministry of Agriculture reported to the World Organization for Animal Health an ongoing outbreak of rabies in dogs on the island of Bali, Indonesia. Rabies has been confirmed in dogs from at least two villages near popular tourist destinations on the southern tip of Bali. At this stage rabies has been identified in animals in only one district but CDC advises travelers to take precautions on the entire island.

<http://wwwn.cdc.gov/travel/content/RabiesBaliIndonesia2008.aspx>

---

*The CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.*

*Links to non-Federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the Federal Government, and none should be inferred. The CDC is not responsible for the content of the individual organizations.*

**Please send us your feedback or comments:** <http://www.cdc.gov/flu/coca/feedback.htm>.

Our Clinician Communication Team is committed to excellence in reporting our weekly updates. Please e-mail [coca@cdc.gov](mailto:coca@cdc.gov) should you note any written errors or discrepancies.

If you need to unsubscribe or update your information, please go to our website:  
<http://emergency.cdc.gov/clinregistry/userMaintenance2.asp>

If you need further information or technical help, please send an e-mail message to: [coca@cdc.gov](mailto:coca@cdc.gov)



#### Communicating With Clinicians

CDC currently employs several mechanisms to communicate with clinicians on topics of urgent concern and interest.

[Download this flyer to find out more](#)



